CDKL5 and craniodiaphyseal dysplasia: Massimiliano Bianchi (CEO of Ulysses Neuroscience) discussed the translational work that his team, as well as other pharmaceutical companies (e.g., Roche, Ultragenyx, Takeda), are doing to develop biomarkers and treatments for CDD resulting from mutations in the CDKL5 gene and affecting 1 in 40,000–60,000 newborns with severe comorbidities, including developmental delay, epilepsy, intellectual disability, dysphagia, dystonia and breathing disturbances (Leonard et al., 2021).